Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
J Cardiol. 2019 Mar;73(3):233-239. doi: 10.1016/j.jjcc.2018.08.008. Epub 2018 Nov 9.
Uric acid (UA), which could provide additional prognostic information in patients with heart failure (HF), can activate sympathetic nerve activity and vice versa, thus creating a vicious cycle in the cardiovascular system. However, it remains unclear whether hyperuricemia (UA>7.0mg/dl) can provide prognostic information independent of sympathetic nerve activity.
UA and potential prognostic variables including sympathetic nerve activity using microneurography (MSNA) were evaluated in 139 patients with HF (ejection fraction<45%). Primary composite cardiovascular endpoints included cardiovascular death and hospitalization due to HF. Predictors for outcomes were analyzed using univariate, multivariable, and Kaplan-Meier analyses. To determine whether the negative impact of hyperuricemia on outcomes is homogenous, prognostic impacts of hyperuricemia were compared in subgroups of HF. Ejection fraction was followed for 9 months after MSNA measurement in 102 patients.
During a follow-up period of 1636 days, 54 patients fulfilled the primary composite endpoint of cardiovascular death or HF hospitalization. Patients with hyperuricemia had a higher cardiovascular event rate than those with normouricemia (p=0.006). On multivariable Cox proportional hazard analysis, hyperuricemia, higher MSNA, and β-blocker dose were independent predictors of cardiovascular events. In subgroup analyses, impact of hyperuricemia on outcome was similar in all subgroups except sympathetic nerve activity (interaction, p=0.033). Hyperuricemia had negative impact on cardiovascular event rates (hazard ratio=3.44) in group with higher MSNA (p=0.0002), but not in those with lower MSNA. Additionally, the change in LVEF was also significantly lower in patients who had a higher MSNA burst incidence and hyperuricemia.
Hyperuricemia might have detrimental effect on prognosis and cardiac function in HF patients with sympathetic overactivation.
尿酸(UA)可在心力衰竭(HF)患者中提供额外的预后信息,它可以激活交感神经活动,反之亦然,从而在心血管系统中形成恶性循环。然而,目前尚不清楚高尿酸血症(UA>7.0mg/dl)是否可以独立于交感神经活动提供预后信息。
在 139 名射血分数<45%的 HF 患者中评估 UA 和潜在的预后变量,包括使用微神经记录法(MSNA)评估的交感神经活动。主要复合心血管终点包括心血管死亡和因 HF 住院。使用单变量、多变量和 Kaplan-Meier 分析来分析预测因素。为了确定高尿酸血症对预后的负面影响是否一致,在 HF 的亚组中比较了高尿酸血症的预后影响。在 102 名接受 MSNA 测量后的 9 个月内,对 EF 进行了随访。
在 1636 天的随访期间,54 名患者出现了心血管死亡或 HF 住院的主要复合终点。高尿酸血症患者的心血管事件发生率高于正常尿酸血症患者(p=0.006)。在多变量 Cox 比例风险分析中,高尿酸血症、更高的 MSNA 和β受体阻滞剂剂量是心血管事件的独立预测因素。在亚组分析中,除了交感神经活动(交互作用,p=0.033)外,高尿酸血症对预后的影响在所有亚组中相似。高尿酸血症对心血管事件发生率有负面影响(危险比=3.44),在交感神经活动较高的组中(p=0.0002),但在交感神经活动较低的组中则没有。此外,在 MSNA 爆发发生率较高且伴有高尿酸血症的患者中,LVEF 的变化也明显较低。
高尿酸血症可能对交感神经过度激活的 HF 患者的预后和心功能产生不利影响。